SPRINGWORKS THERAPEUTICS, INC. (SWTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SWTX Stock Price Chart Interactive Chart >
SWTX Price/Volume Stats
| Current price | $29.18 | 52-week high | $65.92 |
| Prev. close | $29.03 | 52-week low | $13.60 |
| Day low | $28.54 | Volume | 536,015 |
| Day high | $29.61 | Avg. volume | 735,506 |
| 50-day MA | $29.98 | Dividend yield | N/A |
| 200-day MA | $27.16 | Market Cap | 1.82B |
SPRINGWORKS THERAPEUTICS, INC. (SWTX) Company Bio
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Latest SWTX News From Around the Web
Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors– Nirogacestat Treatment Significantly Improved Progression-Free Survival, Objective Response Rate and Key Patient Reported Outcomes – – New Drug Application Under Review by the FDA with PDUFA Action Date of August 27, 2023 – STAMFORD, Conn., March 08, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from the |
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care ConferenceSTAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media |
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights– NDA for Nirogacestat in Adults with Desmoid Tumors Accepted by the FDA and Granted Priority Review; PDUFA Action Date Set for August 27, 2023 – – Topline Data from Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas Expected in the Second Half of 2023 – – Dosed First Patient in Phase 1/2a Combination Study of BGB-3245 and Mirdametinib – – Expanded Intellectual Property Portfolio, Strengthening Protection for Nirogacestat into |
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors– PDUFA Action Date Set for August 27, 2023 –STAMFORD, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with d |
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare ConferenceSTAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, will present today at the 41st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), and a live webcast will be available at ir.springworkstx.com. Ahead of the presentation, the Company highlighted its 2022 accomplishments and announced its a |
SWTX Price Returns
| 1-mo | -3.57% |
| 3-mo | 30.15% |
| 6-mo | 11.93% |
| 1-year | -53.09% |
| 3-year | 10.53% |
| 5-year | N/A |
| YTD | 12.19% |
| 2022 | -58.03% |
| 2021 | -14.53% |
| 2020 | 88.41% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...